Clinical endpoints |
Clinical endpoints |
Clinical endpoints |
Clinical endpoints |
In-hospital mortality |
9 (4.6%) |
6 (12.0%) |
0.053 |
In-hospital mortality (TF-TAVR versus isolated surgical aortic valve
intervention) |
6/176 (3.4%) |
3/40 (7.5%) |
0.447 |
Stroke |
3 (1.6%) |
2 (4.0%) |
0.272 |
Major vascular complication |
15 (7.9%) |
0 (0%) |
0.046 |
Bleeding complications |
Bleeding complications |
Bleeding complications |
Bleeding complications |
Life-threatening |
12 (6.2%) |
6 (12.0%) |
0.161 |
Major |
13 (6.7%) |
14 (28.0%) |
<0.001 |
Life-threatening or major |
25 (12.9%) |
20 (40.0%) |
<0.001 |
Acute kidney injury |
Acute kidney injury |
Acute kidney injury |
Acute
kidney injury |
Stage 1
|
29 (15.0%)
|
15 (30.0%)
|
0.014
|
Stage 2 or 3
|
7 (3.6%)
|
9 (18.0%)
|
<0.001
|
Any stage
|
36 (18.7%)
|
24 (48.0%)
|
<0.001
|
New permanent pacemaker implantation |
27 (13.9%) |
6 (12.0%) |
0.724 |
New onset atrial fibrillation |
14 (7.3%) |
15 (34.9%) |
<0.001 |
Length of ICU stay, days |
1 [1-2] |
3 [1-7] |
<0.001 |
Length of hospital stay, days |
7 [5-10] |
9 [6-16] |
0.005 |
Echocardiographic endpoints |
Echocardiographic endpoints |
Echocardiographic endpoints |
Echocardiographic endpoints |
Aortic regurgitation ≥2 |
20 (10.9%) |
1 (2.6%) |
0.137 |
Aortic regurgitation ≥3 |
10 (5.5%) |
0 (0%) |
0.217 |
Mean aortic gradient, mmHg |
8.6 [6.1-12.0] |
12.0 [8.0-14.0] |
0.007 |